Zollinger–Ellison Syndrome

Publisher Website
Google Scholar
Abstract
THREE decades have elapsed since Zollinger and Ellison first described a syndrome characterized by a severe, often fatal, form of peptic ulcer disease accompanied by marked hypersecretion of gastric acid and non-β islet-cell tumors (gastrinomas) of the pancreas.1 Although the precise incidence of the disease is not known, gastrinomas occur nearly as frequently as insulinomas, and it has been estimated that the Zollinger–Ellison syndrome may be present in up to 0.1 percent of all patients with duodenal ulcer disease in the United States.Historically, treatment of the Zollinger—Ellison syndrome has been directed toward correction of the gastric acid hypersecretion. At . . .